Business Context and Reporting Period
Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company developing a novel class of small molecule antibiotics targeting Gram-positive bacteria. The company's lead candidate, ibezapolstat, is a DNA polymerase IIIC inhibitor designed to treat Clostridioides difficile infection (CDI). The company holds FDA Fast Track and Qualified Infectious Disease Product (QIDP) designations for ibezapolstat. This filing covers the fiscal year ended December 31, 2025.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7.97) million | $(14.10) million |
| Operating Expenses | $8.09 million | $14.12 million |
| Cash and Cash Equivalents (Year-End) | $7.56 million | $3.71 million |
| Working Capital | $5.27 million | $(2.63) million |
| Accumulated Deficit | $(75.29) million | $(67.32) million |
Note: The company has no debt obligations listed in the balance sheet. Liquidity is supported by cash reserves and an Equity Line of Credit (ELOC).
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 43% to $8.09 million in 2025 from $14.12 million in 2024.
- R&D Expenses: Decreased 66% to $1.83 million, driven by reduced consulting fees and manufacturing costs as Phase 2b concluded.
- G&A Expenses: Decreased 28% to $6.26 million, primarily due to lower share-based compensation and professional fees.
- Capital Raising: The company raised approximately $10.6 million in net proceeds from financing activities in 2025, compared to $6.6 million in 2024. Sources included registered direct offerings, an ELOC with Lincoln Park Capital Fund, and a warrant inducement agreement.
- Stock Structure: A 1-for-20 reverse stock split was effected in August 2025 to regain compliance with Nasdaq listing requirements.
Outlook, Risks, and Management Commentary
- Clinical Progress: The company successfully completed Phase 2 trials for ibezapolstat, reporting a 96% clinical cure rate and 100% sustained clinical cure rate in the combined Phase 2a/2b population. The company received FDA and EMA guidance supporting the design of Phase 3 trials.
- Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern. Management states that existing cash resources ($7.6 million) are not sufficient to fund operations for at least 12 months from the issuance of the financial statements.
- Financing Needs: The company anticipates needing substantial additional funding to complete Phase 3 trials and commercialization. Failure to secure capital could force delays or termination of development programs.
- Regulatory Risks: Success depends on obtaining regulatory approval, which is uncertain. The company faces competition from existing antibiotics (vancomycin, fidaxomicin) and microbiologics.
- Subsequent Events: As of March 12, 2026, the company announced a new clinical initiative for recurrent CDI (rCDI) and continued sales under its ELOC.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.6 million cash balance against the projected costs of initiating and completing Phase 3 trials.
- Financing Terms: Review the terms of the Equity Line of Credit (ELOC) with Lincoln Park and the warrant inducement agreement for potential dilution impacts.
- Phase 3 Design: Confirm the specific enrollment targets and statistical power of the upcoming Phase 3 trials as agreed upon with the FDA.
- Going Concern Status: Monitor subsequent filings for evidence of new capital raises or strategic partnerships to mitigate the auditor's going concern qualification.
- Intellectual Property: Verify the expiration dates of key patents (currently extending to September 2030) and the status of regulatory exclusivity (QIDP/Fast Track).